{
    "clinical_study": {
        "@rank": "147874", 
        "arm_group": [
            {
                "arm_group_label": "Healthy control"
            }, 
            {
                "arm_group_label": "clinical high risk subjects for psychosis"
            }
        ], 
        "brief_summary": {
            "textblock": "-  Would be there any difference in dopamine synthesis between remitted clinical high risk\n           subjects for psychosis and healthy control?\n\n        -  What would happen to dopamine synthesis after antipsychotic discontinuation in clinical\n           high risk subjects for psychosis?\n\n        -  What about the dopamine synthesis in recurred clinical high risk subjects for psychosis\n           after the discontinuation?"
        }, 
        "brief_title": "Antipsychotic Discontinuation in High-risk Subjects", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Clinical High Risk for Psychosis", 
            "Antipsychotic Discontinuation", 
            "Presynaptic Dopamine Synthesis", 
            "Glutamate Concentration"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Mental Disorders", 
                "Psychotic Disorders"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Diagnosed as a clinical High Risk\n\n          -  Treated with antipsychotic drugs\n\n          -  PSP1-5 (from SIPS criteria) <3 (severity index)for more than 6 months\n\n          -  Had not experienced a symptomatic relapse in the 6 months\n\n        Exclusion Criteria:\n\n          -  Significant abnormality in laboratory tests\n\n          -  History of head trauma"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "40 Years", 
            "minimum_age": "16 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Clinical high risk subjects for psychosis who have been treated with antipsychotic\n        medication so that reach to the remission."
            }
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 27, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01758887", 
            "org_study_id": "H-1207-055-417"
        }, 
        "intervention_browse": {
            "mesh_term": "Antipsychotic Agents"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "May 18, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Seoul", 
                    "country": "Korea, Republic of", 
                    "zip": "110-744"
                }, 
                "name": "Seoul National University Hospital"
            }
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_groups": "2", 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "Korea: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "measured with [18F]DOPA positron emission tomography", 
                "measure": "Presynaptic dopamine synthesis in the striatum", 
                "safety_issue": "No", 
                "time_frame": "baseline"
            }, 
            {
                "description": "measured using magnetic resonance spectroscopy", 
                "measure": "Glutamate concentration in the frontal lobe", 
                "safety_issue": "No", 
                "time_frame": "baseline"
            }, 
            {
                "description": "measured using [18F]DOPA positron emission tomography", 
                "measure": "Presynaptic dopamine synthesis in the striatum", 
                "safety_issue": "No", 
                "time_frame": "6 months after the baseline"
            }, 
            {
                "description": "measured using magnetic resonance spectroscopy", 
                "measure": "Glutamate concentration in the frontal lobe", 
                "safety_issue": "No", 
                "time_frame": "6 months after the baseline"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01758887"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Seoul National University Hospital", 
            "investigator_full_name": "Jun Soo Kwon", 
            "investigator_title": "Professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "Seoul National University Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Seoul National University Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "December 2012", 
        "study_design": "Observational Model: Case Control, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "May 2013"
    }
}